If you’re eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL), now’s the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, “Not so fast.” While the biotech is undeniably ascendant after getting its first medicine approved for sale in mid-March, the pharma juggernaut […]
Making a million dollars on a stock investment is one of those classic goals you hear many investors say they dream about. And in some rare cases, the dream of a massive return that generates life-changing profits does come true. Investors who took a chance on high-flying Nvidia (NASDAQ: NVDA) back in 2016 and held […]
Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs, and it has been working on diversifying its portfolio to include a wider array of products. Today, the stock has a market capitalization of $115 billion — that’s […]
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful. That group includes Novavax (NASDAQ: NVAX) and Inovio Pharmaceuticals (NASDAQ: INO). The former did launch a coronavirus vaccine in the U.S., […]
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript May 8, 2024 Amphastar Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the Amphastar Pharmaceuticals’ First Quarter Earnings Call. At this time, all participants are […]
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak’s Takeover Bid Valued Up To $7.75/Share On Wednesday, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) confirmed that, since March 2024, it had received several unsolicited proposals from Future Pak LLC to acquire all of Vanda’s outstanding shares. The most recent proposal offered $7.25 – $7.75 per share, subject to certain terms and conditions. The current proposal […]
Vertex Pharmaceuticals (VRTX) will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences (ALPN), the companies said late Wednesday. Alpine stock rocketed almost 21% on rumors of the deal.
Pre-tax profits at the Co Galway-based Chanelle Pharma group decreased by 42 per cent to €13.7 million last year due to higher costs. Earlier this month, vet-turned businessman, Michael Burke sold Chanelle Pharmaceuticals he founded more than 40 years ago in a deal understood to be about €300 million to British private equity group, Exponent. […]
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial implications are massive. But they’re not massive just because it stands to crank out billions in additional revenue. Instead, the plan is to shell […]
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it’s on track to do so again in the field of pain relief. With the latest clinical-trial data pointing to possible development of a winning medicine, there’s reason to believe that more revenue could be on the way. But as […]
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders. Next, Vertex is about to show that it can conquer […]